California Public Employees Retirement System raised its stake in shares of Emergent Biosolutions, Inc. (NYSE:EBS) by 8.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 49,500 shares of the biopharmaceutical company’s stock after buying an additional 3,700 shares during the period. California Public Employees Retirement System owned about 0.12% of Emergent Biosolutions worth $1,679,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in EBS. OppenheimerFunds Inc. raised its stake in Emergent Biosolutions by 23.0% during the 1st quarter. OppenheimerFunds Inc. now owns 12,558 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 2,351 shares during the last quarter. Principal Financial Group Inc. raised its stake in Emergent Biosolutions by 3.9% during the 1st quarter. Principal Financial Group Inc. now owns 277,770 shares of the biopharmaceutical company’s stock valued at $8,066,000 after buying an additional 10,446 shares during the last quarter. Teachers Advisors LLC raised its stake in Emergent Biosolutions by 0.4% during the 1st quarter. Teachers Advisors LLC now owns 371,322 shares of the biopharmaceutical company’s stock valued at $10,783,000 after buying an additional 1,618 shares during the last quarter. Legal & General Group Plc raised its stake in Emergent Biosolutions by 9.3% during the 1st quarter. Legal & General Group Plc now owns 61,140 shares of the biopharmaceutical company’s stock valued at $1,775,000 after buying an additional 5,213 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Emergent Biosolutions by 6.7% during the 1st quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock valued at $109,574,000 after buying an additional 238,194 shares during the last quarter. Institutional investors and hedge funds own 85.67% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/05/california-public-employees-retirement-system-increases-holdings-in-emergent-biosolutions-inc-ebs.html.
In related news, Chairman Fuad El-Hibri sold 25,000 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $38.50, for a total value of $962,500.00. Following the completion of the transaction, the chairman now owns 1,603,763 shares of the company’s stock, valued at approximately $61,744,875.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jerome M. Hauer sold 10,776 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total transaction of $386,104.08. Following the completion of the transaction, the director now directly owns 29,421 shares of the company’s stock, valued at approximately $1,054,154.43. The disclosure for this sale can be found here. Insiders sold a total of 180,227 shares of company stock valued at $6,993,970 over the last 90 days. 16.50% of the stock is currently owned by company insiders.
Shares of Emergent Biosolutions, Inc. (NYSE EBS) opened at $43.03 on Friday. The company has a quick ratio of 6.02, a current ratio of 6.99 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $1,773.35, a price-to-earnings ratio of 22.77, a PEG ratio of 1.32 and a beta of 1.22. Emergent Biosolutions, Inc. has a 12 month low of $24.70 and a 12 month high of $44.86.
Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.41 by $0.32. The firm had revenue of $149.43 million during the quarter, compared to analyst estimates of $124.55 million. Emergent Biosolutions had a return on equity of 14.50% and a net margin of 13.42%. Emergent Biosolutions’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.56 EPS. research analysts anticipate that Emergent Biosolutions, Inc. will post 1.48 earnings per share for the current fiscal year.
A number of brokerages have weighed in on EBS. BidaskClub lowered shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Wells Fargo & Company restated an “outperform” rating and issued a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. Finally, Zacks Investment Research upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price objective for the company in a research note on Wednesday, October 25th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $45.00.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).
What are top analysts saying about Emergent Biosolutions Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Emergent Biosolutions Inc. and related companies.